Syros Pharmaceuticals (SYRS) Rating Lowered to Hold at Zacks Investment Research

Syros Pharmaceuticals (NASDAQ:SYRS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.

According to Zacks, “Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company’s product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “

SYRS has been the topic of a number of other reports. JMP Securities raised Syros Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $33.00 target price on the stock in a report on Thursday, September 28th. Cowen reissued a “buy” rating on shares of Syros Pharmaceuticals in a report on Monday, December 11th. Oppenheimer set a $28.00 target price on Syros Pharmaceuticals and gave the stock a “buy” rating in a report on Monday. ValuEngine lowered Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 22nd. Finally, Roth Capital started coverage on Syros Pharmaceuticals in a report on Monday, October 23rd. They set a “neutral” rating and a $15.00 target price on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. Syros Pharmaceuticals has an average rating of “Buy” and an average target price of $22.23.

Shares of Syros Pharmaceuticals (SYRS) traded up $0.34 during trading on Thursday, hitting $10.73. The stock had a trading volume of 299,600 shares, compared to its average volume of 249,671. Syros Pharmaceuticals has a one year low of $6.30 and a one year high of $24.38. The company has a market cap of $280.85 and a PE ratio of -6.17.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.53). sell-side analysts expect that Syros Pharmaceuticals will post -2.12 earnings per share for the current year.

In other Syros Pharmaceuticals news, Director Srinivas Akkaraju bought 109,774 shares of the firm’s stock in a transaction that occurred on Thursday, December 14th. The shares were acquired at an average cost of $9.03 per share, with a total value of $991,259.22. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Jeremy P. Springhorn acquired 15,000 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was purchased at an average cost of $9.08 per share, for a total transaction of $136,200.00. The disclosure for this purchase can be found here. 33.60% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. GSA Capital Partners LLP acquired a new position in Syros Pharmaceuticals in the 3rd quarter valued at $240,000. Cubist Systematic Strategies LLC acquired a new position in Syros Pharmaceuticals in the 3rd quarter valued at $149,000. Schwab Charles Investment Management Inc. grew its holdings in Syros Pharmaceuticals by 95.8% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 41,709 shares of the company’s stock valued at $614,000 after buying an additional 20,409 shares in the last quarter. Citadel Advisors LLC acquired a new position in Syros Pharmaceuticals in the 3rd quarter valued at $975,000. Finally, Trexquant Investment LP acquired a new position in Syros Pharmaceuticals in the 3rd quarter valued at $282,000. 57.96% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Syros Pharmaceuticals (SYRS) Rating Lowered to Hold at Zacks Investment Research” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://transcriptdaily.com/2018/01/11/syros-pharmaceuticals-syrs-rating-lowered-to-hold-at-zacks-investment-research.html.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply